Overcome challenges of cfDNA purification with high throughput, automated extraction processes

Tuesday, 11th May, 2021, 15:00 - 16:00 CEST.

The use of circulating, cell-free DNA (cfDNA) is rapidly evolving in the clinical landscape. It offers tremendous clinical potential as a screening method for tumor, cancer, fetal DNA studies, disease progression, treatment response, and more. Circulating DNA extraction is often challenging as they are found in low quantities, and accurate methods are needed to isolate the less abundant cfDNA with higher sensitivity and specificity.